GSK3B, glycogen synthase kinase 3 beta, 2932

N. diseases: 393; N. variants: 25
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.570 Biomarker disease BEFREE It requires further study to examine whether abnormality in GSK3β or CRMP2 is also involved in depression phase of BD. 30699850 2019
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.570 Biomarker disease BEFREE As a part of the serotoninergic dysfunction implicated in neurobiology of depression, evidence has focused on serotonin (5-HT) receptors downstream signaling intermediates including glycogen synthase kinase-3β (GSK-3β), cAMP response element binding protein (CREB) and brain derived neurotrophic factor (BDNF). 29291430 2018
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.570 Biomarker disease BEFREE Recent findings of potential implications of glycogen synthase kinase-3β (GSK-3β) dysfunction in psychiatric disorders like depression, have increased focus for development of GSK-3β inhibitors with possible anti-depressant activity. 29421716 2018
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.570 Biomarker disease BEFREE These results show that glycogen synthase kinase-3β may promote the progression of depression. 29036833 2018
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.570 Biomarker disease BEFREE The gene depletion or pharmacological inhibition of GSK-3β reproduces some of the behavioral effects of lithium including reduction of depression- and manic-like behaviors in rodents, which attested the intracellular GSK- 3β inhibition as one of the critical steps in mediating behavioral effect of mood-stabilizers. 29283064 2018
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.570 GeneticVariation disease BEFREE In mood disorder patients, the level of mania (in both acute and stabilized periods) and depression in stabilized periods was positively associated with GSK3B rs12630592 T only in FXR1 rs496250 A-allele carriers (Bonferroni-corrected interaction p=0.024, 0.052 and 0.017 respectively). 28242499 2017
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.570 Biomarker disease PSYGENET Mutant DISC1 affects methamphetamine-induced sensitization and conditioned place preference: a comorbidity model. 21315744 2012
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.570 Biomarker disease PSYGENET Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action. 23188793 2012
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.570 Biomarker disease CTD_human A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. 20534517 2010
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.570 Biomarker disease CTD_human Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. 20357757 2010
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.570 Biomarker disease PSYGENET Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. 17628506 2007
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.570 GeneticVariation disease BEFREE Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. 17628506 2007